Summary of the tumor types for which immune checkpoint blockade therapies are FDA-approved
Tumor type | Therapeutic agent | FDA approval year |
---|---|---|
Melanoma | Ipilimumab | 2011 |
Melanoma | Nivolumab | 2014 |
Melanoma | Pembrolizumab | 2014 |
Non–small cell lung cancer | Nivolumab | 2015 |
Non–small cell lung cancer | Pembrolizumab | 2015 |
Melanoma (BRAF wild-type) | Ipilimumab + nivolumab | 2015 |
Melanoma (adjuvant) | Ipilimumab | 2015 |
Renal cell carcinoma | Nivolumab | 2015 |
Hodgkin lymphoma | Nivolumab | 2016 |
Urothelial carcinoma | Atezolizumab | 2016 |
Head and neck squamous cell carcinoma | Nivolumab | 2016 |
Head and neck squamous cell carcinoma | Pembrolizumab | 2016 |
Melanoma (any BRAF status) | Ipilimumab + nivolumab | 2016 |
Non–small cell lung cancer | Atezolizumab | 2016 |
Hodgkin lymphoma | Pembrolizumab | 2017 |
Merkel cell carcinoma | Avelumab | 2017 |
Urothelial carcinoma | Avelumab | 2017 |
Urothelial carcinoma | Durvalumab | 2017 |
Urothelial carcinoma | Nivolumab | 2017 |
Urothelial carcinoma | Pembrolizumab | 2017 |
MSI-high or MMR-deficient solid tumors of any histology | Pembrolizumab | 2017 |
MSI-high, MMR-deficient metastatic colorectal cancer | Nivolumab | 2017 |
Pediatric melanoma | Ipilimumab | 2017 |
Hepatocellular carcinoma | Nivolumab | 2017 |
Gastric and gastroesophageal carcinoma | Pembrolizumab | 2017 |
Non–small cell lung cancer | Durvalumab | 2018 |
Renal cell carcinoma | Ipilimumab + nivolumab | 2018 |
NOTE: A summary of the tumor indications, therapeutic agents, and year of FDA approval for immune checkpoint blockade therapies. FDA approval includes regular approval and accelerated approval granted as of May 2018. Ipilimumab is an anti-CTLA4 antibody. Nivolumab and pembrolizumab are anti–PD-1 antibodies. Atezolizumab, avelumab, and durvalumab are anti–PD-L1 antibodies. Tumor type reflects the indications for which treatment has been approved. Only the first FDA approval granted for each broad tissue type or indication for each therapeutic agent is noted. In cases where multiple therapies received approval for the same tumor type in the same year, agents are listed alphabetically.
Abbreviations: MSI, microsatellite instability; MMR, mismatch repair.